Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stepwise asthma algorithm trial comparing DuoResp Spiromax-based management versus conventional ICS/LABA/SABA inhaler algorithm
ACTRN12624001488594Phase 4Active, not recruiting
- Sponsor
- Medical Research Institute of New Zealand
- Start
- Apr 2025
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of budesonide + formoterol, Flixocort, salmeterol + fluticasone, fluticasone propionate + vilanterol and salbutamol in asthma (2 arms), sponsored by Medical Research Institute of New Zealand. Primary endpoint: Mean inhaled budesonide equivalent corticosteroid dose per day. Started Apr 2025; status: active, not recruiting.
02
Drugs
budesonide + formoterolFlixocortsalmeterol + fluticasonefluticasone propionate + vilanterolsalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on ACTRN12624001488594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001488594.